SCHEMBL25326356

SCHEMBL25326356

CC(C)(C)OC(=O)N1CC2(CC(Cn3cc(C(F)(F)F)ccc3=O)C2)C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORC P51449 4/20 0.41
GPR119 Q8TDV5 3/20 0.40
TDP1 Q9NUW8 1/20 0.40
EIF2AK4 Q9P2K8 1/20 0.40
MAPT P10636 1/20 0.39
ABHD6 Q9BV23 2/20 0.38
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MGLL Q99685 1/20 0.38
ALDH1A1 P00352 1/20 0.37
TP53 P04637 1/20 0.37
KMT2A Q03164 1/20 0.37
TGFBR1 P36897 1/20 0.36
HTT P42858 1/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
PKM P14618 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30410253 0.84 ABHD6 (0.42) RORCGPR119MAPTABHD6MGLL
SCHEMBL25324873 0.82 GPR119 (0.37) RORCGPR119EIF2AK4MGLL
SCHEMBL30410383 0.79 MGLL (0.41) RORCGPR119EIF2AK4MAPTMGLL
SCHEMBL30775963 0.77 GPR119 (0.36) RORCGPR119ABHD6
SCHEMBL30775975 0.76 ROCK2 (0.38) RORCGPR119
SCHEMBL18357554 0.76 ABHD6 (0.53) RORCGPR119MAPTABHD6MGLL
SCHEMBL30409731 0.75 MGLL (0.40) TDP1MAPTMGLLKMT2AHTT
SCHEMBL30775971 0.75 GPR119 (0.36) RORCGPR119
SCHEMBL30700632 0.75 RORC (0.42) RORCGPR119MAPTABHD6MGLL
SCHEMBL30775994 0.75 TDP1 (0.43) TDP1MAPTLMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 RORC 1177/4885GPR119 1935/4885TDP1 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.